Jonathan has extensive experience of working with clients in a wide range of technology areas including agri-tech, sustainability, pharmaceuticals, chemistry, therapeutic treatments, personal care devices, medical devices, medical diagnostics, healthcare, biotechnology, regenerative stem cell therapies, food packaging, gene-editing (CRISPR), CAR-T cell-based therapies, materials, catalysts, energy technologies and cosmetics.
Jonathan manages a number of global patent portfolios for start-ups and SME clients, and his burgeoning practice has a particular focus on start-up and spin-out companies.
Providing his clients with strategic, value-driven advice, Jonathan understands what clients need from their IP portfolio. He has been involved with numerous due diligence exercises for investment rounds, acquisition and licensing, and listings on the UK AIM stock exchange and the Nasdaq in the US.
Jonathan also has an extensive registered design practice and handles the portfolios of European and UK registered designs for a number of household-name international clients.
Prior to joining Keltie in 2011, Jonathan was a principal chemist at GlaxoSmithKline and has almost 10 years’ experience of working in the pharmaceutical sector in the epigenetic, immuno-inflammation, cardiovascular and respiratory disease areas.
Jonathan received a first-class honours degree in Natural Sciences from the University of Cambridge before gaining a PhD in organic chemistry with post-doctoral experience at the distinguished École Polytechnique, Paris, France.
23.02.2021Patenting ethical, environmental or socially responsible technologies
Can patent protection ever be part of an ethical or high moral value business model?
16.12.2020Insights into the automotive sector with Joanne Hopley
Joanne Hopley talks about the future of automotive.
OtherLess related knowledge